Literature DB >> 18678140

Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification.

Emmanuel J Favaloro1, Roslyn Bonar, Katherine Marsden.   

Abstract

UNLABELLED: von Willebrand disease (VWD) is the most common inherited bleeding ailment, and is characterised by low levels of, or abnormal function in, the plasma protein von Willebrand factor (VWF). However, the laboratory testing process is problematic because of both the heterogeneity of VWD and the limitations in the tests used to identify reduced or abnormal VWF.
OBJECTIVE: This study reports on the lower levels of sensitivity for the different assays used in the diagnostic process for VWD and their significance in the diagnostic identification and classification ofVWD.
METHODS: The RCPA Haematology QAP is an international external quality assurance (EQA) program that includes VWF/VWD testing within one of its special haemostasis modules. Over the past 10 years, over 50 samples have been distributed to participants, including five samples devoid of VWF and derived from either true Type 3 VWD patients or else from commerciallypurchased VWF deficient plasma. Samples were tested blind by study participants, who report back both numerical values (for VWF and Factor VIII:C) and an interpretation regarding whether or not VWD is suggested by laboratory findings, and if so, the probable VWD subtype.
RESULTS: Returned data indicates that the lower level of sensitivity (LLS) tends to be around 5-10U/dL for Factor VIII:C, VWF antigen(VWF:Ag), VWFcollagen binding (VWF:CB), and VWF 'activity' (VWF:Act), but canreach 20U/dL or more for VWF ristocetin cofactor (VWF:RCo). There does not appear to be any improvement over the past decade despite ongoing automation of methodology, and indeed, automation does not seem to provide better LLS performance.
CONCLUSIONS: Limitations in the LLS of VWD testing have significant implications in terms of the identification and classification of an individual's VWD, given that these laboratory assays are used to identify VWD andhelp characterise functional VWF discordance, and that the majority of severe VWD subtypes have levels of VWF below 20U/dL. Thus, laboratories will sometimes be unable to distinguish whether VWF deficient samples derive from Type 3 VWD or severe Type 1 VWD or even Type 2 VWD.

Entities:  

Mesh:

Year:  2008        PMID: 18678140

Source DB:  PubMed          Journal:  Clin Lab Sci        ISSN: 0894-959X


  5 in total

1.  Rapid discrimination of the phenotypic variants of von Willebrand disease.

Authors:  Jonathan C Roberts; Patti A Morateck; Pamela A Christopherson; Ke Yan; Raymond G Hoffmann; Joan Cox Gill; Robert R Montgomery
Journal:  Blood       Date:  2016-02-25       Impact factor: 22.113

Review 2.  Laboratory aspects of von Willebrand disease: test repertoire and options for activity assays and genetic analysis.

Authors:  G Castaman; A Hillarp; A Goodeve
Journal:  Haemophilia       Date:  2014-05       Impact factor: 4.287

3.  Autosomal dominant C1149R von Willebrand disease: phenotypic findings and their implications.

Authors:  Almudena Pérez-Rodríguez; Aranzazu García-Rivero; Esther Lourés; Maria Fernanda López-Fernández; Angela Rodríguez-Trillo; Javier Batlle
Journal:  Haematologica       Date:  2009-03-13       Impact factor: 9.941

Review 4.  New developments in von Willebrand disease.

Authors:  Helen Fogarty; Dearbhla Doherty; James S O'Donnell
Journal:  Br J Haematol       Date:  2020-05-12       Impact factor: 6.998

5.  Comparing the quality of testing for von Willebrand disease in different geographic localities.

Authors:  Emmanuel J Favaloro
Journal:  Haemophilia       Date:  2022-01-31       Impact factor: 4.263

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.